IDEAYA Biosciences heads into its May 6 earnings release with a noteworthy split between short sellers building exposure and options traders positioned for upside rather than protection.
Short interest has climbed sharply. It rose nearly 14% over the past month to just under 12% of the free float — roughly 10.5 million shares — with most of that build concentrated in the final week of April. Days to cover are running at 4.5 sessions, according to official FINRA data. Yet the borrow market itself shows no signs of stress: the cost to borrow remains close to its lowest readings in months at around 0.53% annually, and availability is loose. That combination — rising short interest alongside cheap, easily available borrow — points to a considered directional bet rather than a squeeze-vulnerable position.
Options positioning contradicts the short sellers' caution. The put/call ratio is running well below its 20-day average at 0.25, near the more bullish end of the past year's range, with the 52-week low just above zero. Call activity is dominating — a signal that a meaningful cohort of market participants is leaning into positive news flow from the print, not hedging against it. That divergence is the defining tension heading into today's release.
The analyst community has been broadly constructive, though the lone holdout gives the bull/bear debate shape. In mid-April, RBC Capital, Wedbush, and Guggenheim all raised targets — to $53, $58, and $54 respectively — while Goldman Sachs lifted its target to $35 but held at Neutral and kept its distance from the positive chorus. Wells Fargo moved its Overweight target to $48. The mean target across the Street sits around $52.80, which implies roughly 83% upside from the current price of $28.80 — a gap that reflects the market's cautious re-rating of the stock since it fell 12% over the past month. The bull thesis centres on the company's precision oncology pipeline and biomarker-driven approach; bears focus on competitive pressure in the metastatic uveal melanoma space and the typical execution risks that come with a developmental-stage pipeline burning approximately $308 million in operating cash annually.
One genuine standout in the ownership data is independent director Jeffrey Stein's open-market purchase of 50,000 shares in early March at roughly $32.96, committing $1.65 million at a price above where the stock trades today. That is a relatively uncommon form of conviction from a board member ahead of a reporting period. State Street and T. Rowe Price both added meaningfully to positions in the most recent filing period, and FMR holds close to 15% of shares outstanding — the largest single block. Against prior earnings prints, the stock has managed small positive first-day moves on two of the last three occasions, with five-day reactions also positive; the lone down print was a modest 2.4% decline.
The print is less a test of whether the pipeline is advancing and more a question of whether management can articulate a timeline that closes the gap between a $28 stock and a Street consensus pointing toward $50-plus.
See the live data behind this article on ORTEX.
Open IDYA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
